SiyoMicro raises 100M CNY to scale microbial cell factories
What's the deal? Chinese biotech SiyoMicro has raised 100 million CNY (about $14.8 million) in a round led by Aier Eye Hospital GroupDealroom has a profile for this one. Try Dealroom →, with participation from Goldport CapitalDealroom has a profile for this one. Try Dealroom →, the Zhongguancun Qihang FundDealroom has a profile for this one. Try Dealroom → and the Longgang Guidance Fund. The startup describes itself as an AI-plus-biotechnology company building microbial cell factories.
What's the endgame? SiyoMicro develops bioactive ingredients for the global cosmetics, functional food, and flavour and fragrance industries. Its focus is high-value materials produced through engineered microbes rather than traditional extraction.
What's the money for? The company will direct the funds toward building its synthetic biology platform. That includes speeding up multi-chassis cell development, moving products toward commercial-scale production, and setting up a strategic position in bulk bio-manufacturing.
The signal: The backing of an industrial investor like Aier Eye Hospital Group, alongside a government guidance fund, points to continued appetite for synthetic biology as a route to specialty ingredients — and for turning lab-stage microbes into industrial supply.
Read more: ITjuzi
Image credit: Alexander van Dijk
